Structure via PubChem · Public domain (PubChem)
Riluzol
Sign in to saveRiluzole is a medication used to treat amyotrophic lateral sclerosis (ALS) and other motor neuron diseases. Riluzole delays the onset of ventilator-dependence or tracheostomy in some people and may increase survival by two to three months. Riluzole is available in tablet and liquid form. A thin film version of riluzole which dissolves on the tongue (commercially known as Exservan or Emylif) is available in the United States and United Kingdom.
Chemical data
- Formula
- C8H5F3N2OS
- Molecular weight
- 234.2 g/mol
- IUPAC name
- 6-(trifluoromethoxy)-1,3-benzothiazol-2-amine
- SMILES
- C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N
- InChIKey
- FTALBRSUTCGOEG-UHFFFAOYSA-N
- XLogP
- 3.6
- Polar surface area
- 76.4 Ų
- H-bond donors
- 1
- H-bond acceptors
- 7
- Formal charge
- 0
via PubChem
Research
2,265 papers- Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).The Cochrane database of systematic reviews · 2012
- The pharmacology and mechanism of action of riluzole.Neurology · 1996
- Riluzole for the treatment of amyotrophic lateral sclerosis.Neurodegenerative disease management · 2020
- A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.The New England journal of medicine · 1994
- Riluzole.Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases · 2000
via PubMed